Zanidatamab in HER2-Positive Metastatic Biliary Tract Cancer
Shubham Pant(The University of Texas MD Anderson Cancer Center), Omkar Marathe, Madappa N. Kundranda(The University of Texas MD Anderson Cancer Center), Laëtitia Dahan, Ari David Baron, Marine Jary, Filippo de Braud(University of Milan), Mohamedtaki Abdulaziz Tejani(AdventHealth Orlando), Muhammad Shaalan Beg, Elisabetta Fenocchio(Candiolo Cancer Institute), J. Adeva Alfonso, Hui‐Chuan Sun(Fudan University), Myung Ah Lee(The Catholic University of Korea Seoul St. Mary's Hospital), Lequn Bao(Hubei Cancer Hospital), Roopinder Gillmore, Daneng Li(City Of Hope National Medical Center), Jieer Ying(Chinese Academy of Medical Sciences & Peking Union Medical College), Laura Layos, Sara Lonardi(Istituto Oncologico Veneto), Massimo Aglietta(Verizon (United States)), Antonio Cubillo Gracián(Hospital Universitario HM Sanchinarro), Do‐Youn Oh(Seoul National University Hospital), Jung Hun Kang(Gyeongsang National University Hospital), Emerson Y. Chen(Oregon Health & Science University), Harpreet Wasan(Hammersmith Hospital), Eric X. Chen(Princess Margaret Cancer Centre), Jean‐Philippe Metges(Centre Hospitalier Régional Universitaire de Brest), Ghassan K. Abou‐Alfa(Memorial Sloan Kettering Cancer Center), Teresa Macarulla(Vall d'Hebron Hospital Universitari), John Bridgewater(University College London Hospitals NHS Foundation Trust), Michel Ducreux(Université Paris-Saclay), Olumide Gbolohon, Jin Won Kim(Korea University Medical Center), Jia Fan(Nanjing Tech University), Ying Cheng(First Affiliated Hospital of Xi'an Jiaotong University), Yi Zhao(Beijing Enterprises (China)), Xiaotian Wu(Jazz Pharmaceuticals (United States)), Yuanyuan Bao(BeiGene (China)), Hye Jin Choi(Yonsei University), Jonathon Gable(Jazz Pharmaceuticals (United States)), Paula Carrasco Aguirre, Heung-Moon Chang(Asan Medical Center), Feng Xie(Chinese People's Liberation Army), Gentry George King, Milind Javle(The University of Texas MD Anderson Cancer Center), James J. Harding(Memorial Sloan Kettering Cancer Center), Yixing Jiang, Tingbo Liang(Zhejiang University), Phillip M. Garfin(Zymeworks (Canada))
Cited by 7
Related Papers
Cisplatin plus Gemcitabine versus Gemcitabine for Biliary Tract Cancer
|New England Journal of Medicine|2010|4.5k
Leucovorin and Fluorouracil With or Without Oxaliplatin as First-Line Treatment in Advanced Colorectal Cancer
|Journal of Clinical Oncology|2000|3.8k
Nivolumab in patients with metastatic DNA mismatch repair-deficient or microsatellite instability-high colorectal cancer (CheckMate 142): an open-label, multicentre, phase 2 study
|The Lancet Oncology|2017|2.8k
Pembrolizumab in patients with advanced hepatocellular carcinoma previously treated with sorafenib (KEYNOTE-224): a non-randomised, open-label phase 2 trial
|The Lancet Oncology|2018|2.5k
Cholangiocarcinoma 2020: the next horizon in mechanisms and management
|Nature Reviews Gastroenterology & Hepatology|2020|2.5k